USPTO serial 87436387
IQVIA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 16, 2018
- Examiner
- EBAUGH, MICHAEL
- Law office
- Historical data usage
What this means
Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.
Need help with IQVIA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
PARSIPPANY, NJ, US
PARSIPPANY, NJ, US
PARSIPPANY, NJ, US
Parsippany, NJ, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Cynthia Johnson Walden
Cynthia Johnson Walden FISH & RICHARDSON P.C.PO BOX 1022MINNEAPOLIS, MN 55440-1022United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable audio materials, audio-visual materials, video materials, written materials, and visual materials in the field of pharmaceutical, medical, healthcare, and life sciences information and analysis; Downloadable electronic publications in the nature of brochures, reports and white papers in the pharmaceutical, medical, healthcare and life sciences fields; Computer software, mobile applications and instructional manuals sold as a unit therewith, for use in data collection, data management and data analysis of pharmaceutical, medical, healthcare, and life sciences information; Computer software, mobile applications and instruction manuals sold as a unit therewith, for healthcare management, namely, patient, prescriber, payor and employee management; Electronic database recorded on computer media containing pharmaceutical, medical, healthcare, and life sciences information; Computer software for collecting, managing, and analyzing clinical trial data and information in the pharmaceutical, medical, healthcare and life sciences fields; Computer hardware and software for healthcare management and electronic health record (EHR) management; Computer software for collecting, managing, and analyzing data related to patient registries, quality improvement, patient support, and patient management in the pharmaceutical, medical, healthcare, and life sciences fields | ACTIVE | Nov 7, 2017 |
| 035 | Market analysis and research services; Business market consulting; Marketing consulting; Business consulting and information services; Business consulting services and business management consulting in the pharmaceutical, medical, healthcare, and life sciences fields; Business process outsourcing services in the pharmaceutical, medical, healthcare, and life sciences fields; Providing a web-based online portal that provides customer access to business information in the pharmaceutical, medical, healthcare, and life sciences fields; Public policy research services; Computerized database management and data processing services in the pharmaceutical, medical, healthcare, and life sciences fields; Sales representatives in the pharmaceutical, medical, healthcare, and life sciences fields; Business consultation and management regarding marketing activities, launching of new products and services, and sales; Personnel recruitment and placement; Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of pharmaceutical, medical, healthcare, and life sciences companies to assist them with clinical research, clinical trials and applications for drug, biologic and device approval; Providing independent review of clinical trials for business purposes; Maintaining a registry of patients, namely, compilation of patient information into computer databases; Business consulting and business management consultation services related to healthcare management and electronic health records management; Business management consulting and advisory services in pharmaceutical, medical, healthcare, and life sciences fields; Advertising, marketing and promotional services in the pharmaceutical, medical, healthcare, and life sciences fields; Business management services, namely, quality management services for establishing business quality policies for patient-care program; Recruitment services, namely, advertising clinical trials, recruiting patients, and placing patients for participation in clinical trials for testing of drugs, biologics and devices; Business consulting in the fields of healthcare management | ACTIVE | Nov 7, 2017 |
| 041 | Education and training services, namely, conducting training programs, seminars, classes, conferences and workshops in the pharmaceutical, medical, healthcare, and life sciences fields; Educational and training services, namely, conducting conferences to train physicians and other medical providers on conducting clinical trials; Education and training services, namely, providing non-downloadable webinars, webcasts and digital content in the form of podcasts in the pharmaceutical, medical, healthcare, and life sciences fields; Non-downloadable online publications in the nature of brochures, reports, or white papers in the pharmaceutical, medical, healthcare, and life sciences fields; Medical evaluation and education services, namely, education in the form of individual training and classes for training of patients, physicians and other healthcare providers on disease and treatment management | ACTIVE | Nov 7, 2017 |
| 042 | Providing online, non-downloadable software providing pharmaceutical, medical, healthcare, and life sciences information and analysis; Software as a service (SAAS) services featuring software providing, collecting, analyzing pharmaceutical, medical, healthcare, and life sciences information; Computer services, namely, providing on-line, non-downloadable computer software used for accessing, collecting, managing, tracking, analyzing, and reporting data in the pharmaceutical, medical, healthcare, and life sciences fields; Research in the field of pharmaceutical, medical, healthcare, and life sciences information; Computer services, namely, designing, developing and maintaining application software and databases in the field of pharmaceutical, medical, healthcare, and life sciences information; Computer software development for others; Clinical research, clinical testing, and laboratory testing services in the pharmaceutical, medical, healthcare, and life sciences fields; Product development consultation in the pharmaceutical, medical, healthcare, medical and life sciences fields; Conducting clinical trials for others; Providing temporary use of on-line non-downloadable software for use in healthcare and electronic health record management; Information technology consulting services; Computer software consultation services in the pharmaceutical, medical, healthcare, and life sciences fields; Scientific research in the pharmaceutical, medical, healthcare, and life sciences fields; Computer services, namely, creating computer network-based indexes and databases of information; Providing electronic data capture and data management systems, namely, providing temporary use of online, non-downloadable software for collection and management of healthcare and life sciences data; Providing temporary use of online, non-downloadable computer software for collecting, managing, and analyzing clinical trial data; Providing an on-line interactive database featuring scientific research information in the pharmaceutical, medical, healthcare, and life sciences fields; Providing scientific information relating to the development, validation, and regulatory approval of pharmaceutical drugs, biologics, and medical devices; Providing technical information relating to the development and validation of pharmaceutical drugs, biologics, and medical devices | ACTIVE | Nov 7, 2017 |
| 044 | Providing health, medical, pharmaceutical, health management and disease management information to others | ACTIVE | Nov 7, 2017 |
| 045 | Regulatory compliance legal research in the field of development of drugs, devices, biologics and methodologies used in the pharmaceutical industry, and medical industry; Regulatory compliance consulting in the pharmaceutical, medical, healthcare, and life sciences fields; Providing regulatory information, namely, legal information regarding compliance with pharmaceutical, medical, healthcare, and life sciences regulations; Providing regulatory implementation services, namely, regulatory compliance consulting, in the fields of the development, validation, and production of drugs, biologics and devices; Providing an online, interactive computer database in the field of regulatory affairs relating to the pharmaceutical, medical, healthcare, and life sciences fields | ACTIVE | Nov 7, 2017 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by IQVIA INC.
- Other trademarks owned by IQVIA INC.
- Other trademarks owned by IQVIA INC.
- Other trademarks owned by Quintiles IMS Incorporated
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named IQVIA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 5, 2026 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Feb 19, 2025 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Feb 19, 2025 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Feb 19, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 11, 2024 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Oct 16, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Oct 17, 2018 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Oct 16, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 31, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 31, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 11, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 20, 2018 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jun 18, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 16, 2018 | AAUA | NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED | — |
| Jun 15, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 15, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 15, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 15, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 15, 2018 | IUAA | USE AMENDMENT ACCEPTED | — |
| Jun 6, 2018 | AUPC | AMENDMENT TO USE PROCESSING COMPLETE | — |
| Jun 6, 2018 | IUAF | USE AMENDMENT FILED | — |
| Jun 5, 2018 | EAAU | TEAS AMENDMENT OF USE RECEIVED | — |
| Mar 16, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 16, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 16, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 9, 2018 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Feb 20, 2018 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Feb 6, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 6, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 6, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 6, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 6, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 8, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 8, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 8, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 2, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| May 10, 2017 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| May 9, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 8, 2017 | NWAP | NEW APPLICATION ENTERED | — |